The results were so positive it was deemed unethical to keep giving people placebo instead of Invokana, an SGLT-2 inhibitor approved for type 2 diabetes
Complications
Higher blood sugar levels cause damage over time to blood vessels and nerves, which can affect your eyes, heart, kidneys, and other organs. It’s important to be aware of these diabetes-related health complications so that you can act now to avoid them or prevent them from progressing.
18 readers recommended
17 readers recommended
The S-ICD is an FDA-approved device that can prevent sudden cardiac arrest; this trial is testing it in people with diabetes who’ve had prior heart attacks with...
15 readers recommended
Foot and hand cream, moisturizing cream, and cleansing wash now available at Walgreens, Target, and Amazon.com
21 readers recommended
FDA updates Invokana label – the type 2 diabetes therapy now improves heart health in type 2’s with established heart disease in addition to glucose lowering
13 readers recommended
New guidelines by the US Department of Health and Human Services emphasize the benefit of ANY increased physical activity
16 readers recommended
Results from the CREDENCE trial suggest that Invokana’s kidney benefits exist on top of blood pressure lowering medications (standard of care)
12 readers recommended
Eylea can help reduce the risk of vision loss, a common complication of diabetes
30 readers recommended
A recent study found 38% of those with type 1 diagnosed after age 30 were not initially given insulin; learn ways of differentiating between type 1 and type 2 at...
28 readers recommended
A study recruiting 10,000 people will look at whether Zynquista (sotagliflozin) has effects beyond glucose-lowering and weight loss
15 readers recommended
A new study will investigate whether SGLT-2 inhibitor Farxiga can delay the progression of heart failure in people with and without type 2 diabetes
27 readers recommended
Heart benefits of the SGLT-2 inhibitor pill beyond blood sugars and weight loss for people with type 2 diabetes
15 readers recommended
Recently announced results from the REWIND and EMPRISE studies show heart protective effects of GLP1-agonist Trulicity and SGLT-2 inhibitor Jardiance in people with and...
53 readers recommended
SGLT-2 inhibitors and GLP-1 agonists recommended as first-line therapies; Farxiga offers heart health benefits in people with and without diabetes
18 readers recommended
A new premixed, liquid glucagon coming in October in a prefilled syringe and in 2020 as an auto-injector. The second stable glucagon approved this year
25 readers recommended
A trial is enrolling over 3,000 individuals living with type 2 diabetes and chronic kidney disease
15 readers recommended
The SGLT-2 inhibitor becomes the first diabetes medicine approved to treat kidney disease and reduce the risk of hospitalization for heart failure in people with type 2...
14 readers recommended
When first diagnosed, Renza was told to fear diabetes complications. This clouded her ability to do even the most basic of self-management
10 readers recommended
Farxiga’s heart health benefits were the same in people with and without diabetes, as well as across a spectrum of baseline A1C levels
10 readers recommended
Are people aware of the link between diabetes and heart health? Do they know that certain diabetes drugs may protect the heart? Is heart health commonly discussed with...
12 readers recommended
New guidelines from ADA and EASD focus on GLP-1 agonists and SGLT-2 inhibitors to improve heart and kidney health